Ranibizumab news

All news on Ranibizumab (also known as Lucentis and Susvimo): plants, production capacities, investments and involved companies.

30 April 2026

Roche to present ophthalmology portfolio data at ARVO 2026

ARVO 2026: real‑world data show Vabysmo reduces retinal fluid in nAMD/DME; Susvimo enables sustained delivery with lower treatment burden; early vamikibart IL‑6 results; 45+ abstracts.
29 April 2026

Genentech to present ophthalmology data at ARVO 2026

ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts
17 October 2025

Roche Unveils Phase III Data for Vamikibart in Uveitic Macular Edema

Vamikibart shows promise in treating UME, with significant vision improvements in trials, offering a non-steroid alternative with fewer side effects.
4 September 2025

Roche's Contivue with Susvimo Receives CE Mark for nAMD Treatment

Contivue with Susvimo offers continuous nAMD treatment, showing stable long-term vision outcomes with up to two refills yearly, backed by seven-year LADDER study data.

Who will be producing Ranibizumab in the future?

Find out with chemXplore Alpha

Learn more